These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23624973)

  • 1. Awaiting evidence of neuroprotective effects of recombinant erythropoietin in very preterm infants.
    Dame C
    J Perinatol; 2013 May; 33(5):411. PubMed ID: 23624973
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to dr C dame.
    McAdams RM; McPherson RJ; Juul SE
    J Perinatol; 2013 May; 33(5):412. PubMed ID: 23624974
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes of extremely low birth weight infants given early high-dose erythropoietin.
    McAdams RM; McPherson RJ; Mayock DE; Juul SE
    J Perinatol; 2013 Mar; 33(3):226-30. PubMed ID: 22722674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety.
    Juul SE; McPherson RJ; Bauer LA; Ledbetter KJ; Gleason CA; Mayock DE
    Pediatrics; 2008 Aug; 122(2):383-91. PubMed ID: 18676557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial.
    Natalucci G; Latal B; Koller B; Rüegger C; Sick B; Held L; Bucher HU; Fauchère JC;
    JAMA; 2016 May; 315(19):2079-85. PubMed ID: 27187300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.
    Fauchère JC; Dame C; Vonthein R; Koller B; Arri S; Wolf M; Bucher HU
    Pediatrics; 2008 Aug; 122(2):375-82. PubMed ID: 18676556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants.
    Neubauer AP; Voss W; Wachtendorf M; Jungmann T
    Ann Neurol; 2010 May; 67(5):657-66. PubMed ID: 20437563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report.
    Luciano R; Fracchiolla A; Ricci D; Cota F; D'Andrea V; Gallini F; Papacci P; Mercuri E; Romagnoli C
    Ital J Pediatr; 2015 Sep; 41():64. PubMed ID: 26376632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection with erythropoietin in preterm and/or low birth weight infants.
    Zhang J; Wang Q; Xiang H; Xin Y; Chang M; Lu H
    J Clin Neurosci; 2014 Aug; 21(8):1283-7. PubMed ID: 24650681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants.
    Bierer R; Peceny MC; Hartenberger CH; Ohls RK
    Pediatrics; 2006 Sep; 118(3):e635-40. PubMed ID: 16908620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Early High-Dose Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants.
    Fauchère JC; Koller BM; Tschopp A; Dame C; Ruegger C; Bucher HU;
    J Pediatr; 2015 Jul; 167(1):52-7.e1-3. PubMed ID: 25863661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Early Erythropoietin for Neuroprotection in Preterm Infants: A Meta-analysis.
    Fischer HS; Reibel NJ; Bührer C; Dame C
    Pediatrics; 2017 May; 139(5):. PubMed ID: 28557760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants.
    Brown MS; Eichorst D; Lala-Black B; Gonzalez R
    Pediatrics; 2009 Oct; 124(4):e681-7. PubMed ID: 19786428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates.
    Ohls RK; Christensen RD; Widness JA; Juul SE
    J Pediatr; 2015 Jul; 167(1):10-2. PubMed ID: 25917767
    [No Abstract]   [Full Text] [Related]  

  • 15. [Early nutrition and the development of the preterm infant].
    Lapillonne A
    Arch Pediatr; 2010 Jun; 17(6):711-2. PubMed ID: 20654854
    [No Abstract]   [Full Text] [Related]  

  • 16. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age.
    Kaufman DA; Cuff AL; Wamstad JB; Boyle R; Gurka MJ; Grossman LB; Patrick P
    J Pediatr; 2011 May; 158(5):759-765.e1. PubMed ID: 21168853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limits of viability: definition of the gray zone.
    Seri I; Evans J
    J Perinatol; 2008 May; 28 Suppl 1():S4-8. PubMed ID: 18446176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can erythropoietin improve developmental outcomes for preterm infants?
    McPherson RJ
    Pediatrics; 2009 Oct; 124(4):e805-6. PubMed ID: 19770176
    [No Abstract]   [Full Text] [Related]  

  • 19. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants.
    Watterberg KL; Shaffer ML; Mishefske MJ; Leach CL; Mammel MC; Couser RJ; Abbasi S; Cole CH; Aucott SW; Thilo EH; Rozycki HJ; Lacy CB
    Pediatrics; 2007 Jul; 120(1):40-8. PubMed ID: 17606560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants.
    Schneider JK; Gardner DK; Cordero L
    Pharmacotherapy; 2008 Nov; 28(11):1335-40. PubMed ID: 18956993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.